The pioglitazone safety warning issued in South Korea, which recommended prescribing with careful attention among those with high risk of bladder cancer, led to a moderate decrease in pioglitazone users.
In-Sun Oh, BA
Advertisement
Articles by In-Sun Oh, BA
Advertisement
Latest Updated Articles
- Prescribing Trend of Pioglitazone After Safety Warning Release in Korea
Published: November 19th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
2
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
3
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
4
AMCP Nexus Bringing the Latest on Health Policy, Drug Access, and Value-Based Care
5
